Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genmab A/S Sponsored ADR (GMAB : NSDQ)

• Company Description    Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. Number of Employees: 2,682

• Price / Volume Information    Yesterday's Closing Price: $30.80 Daily Weekly Monthly 20 Day Moving Average: 1,331,548 shares Shares Outstanding: 642.38 (millions) Market Capitalization: $19,785.43 (millions) Beta: 0.90 52 Week High: $33.96 52 Week Low: $17.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.81% -3.65% 12 Week -3.30% -4.86% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL CARL JACOBSENS VEJ 30 - VALBY,G7 2500 DNK ph: 45-7020-2728 fax: - ir@genmab.com http://www.genmab.com

• General Corporate Information    Officers Jan G. van de Winkel - President and Chief Executive Officer Deirdre P. Connelly - Chair Anthony Mancini - Chief Operating Officer Anthony Pagano - Executive Vice President and Chief Financial Offic Birgitte Stephensen - Executive Vice President and Chief Legal Officer Peer Information Genmab A/S Sponsored ADR (CORR.) Genmab A/S Sponsored ADR (RSPI) Genmab A/S Sponsored ADR (CGXP) Genmab A/S Sponsored ADR (BGEN) Genmab A/S Sponsored ADR (GTBP) Genmab A/S Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 372303206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/11/26 Share - Related Items Shares Outstanding: 642.38 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $19,785.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.55 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 10.17% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/11/26

• Fundamental Ratios P/E Current FY Estimate: 19.82 Trailing 12 Months: 14.88 PEG Ratio: 1.95 Price Ratios Price/Book: 3.44 Price/Cash Flow: 20.31 Price / Sales: 5.52 EPS Growth vs. Year Ago Period: 124.14% vs. Previous Quarter: 20.37% Sales Growth vs. Year Ago Period: 25.23% vs. Previous Quarter: 10.49% ROE 12/31/25 - - 09/30/25 - 23.98 06/30/25 - 21.03 ROA 12/31/25 - - 09/30/25 - 19.45 06/30/25 - 16.98 Current Ratio 12/31/25 - - 09/30/25 - 6.03 06/30/25 - 6.22 Quick Ratio 12/31/25 - - 09/30/25 - 6.01 06/30/25 - 6.20 Operating Margin 12/31/25 - - 09/30/25 - 36.25 06/30/25 - 32.11 Net Margin 12/31/25 - - 09/30/25 - 41.36 06/30/25 - 37.53 Pre-Tax Margin 12/31/25 - - 09/30/25 - 46.57 06/30/25 - 42.63 Book Value 12/31/25 - - 09/30/25 - 8.96 06/30/25 - 8.26 Inventory Turnover 12/31/25 - - 09/30/25 - 17.07 06/30/25 - 16.81 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©